重组人p53腺病毒注射液联合化疗治疗恶性体腔积液的疗效观察  

Treatment of Malignant Body Cavity Effusion with Recombinate Human p53 Adenovirus Injection Combining Chemotherapy: Observation of Clinical Effects

作　　者：曹信杰 张颖[1] 李会兰[1] 王会平[1] 王志勇[1] 魏莉[1] 

机构地区：[1]河北秦皇岛市海港医院,秦皇岛市066000

出　　处：《中国药房》2005年第23期1809-1810,共2页China Pharmacy

摘　　要：目的:评价重组人p53腺病毒注射液(rAd-p53)联合化疗治疗恶性体腔积液的疗效。方法:50例恶性体腔积液患者随机分为治疗组与对照组,治疗组行穿刺引流后腔内注射rAd-p531×1012VP,在rAd-p53注射后48h体腔内再注入顺铂60mg/m2,1次/wk,疗程3wk^4wk;对照组除不给予rAd-p53外,腔内化疗与治疗组相同。结果:治疗组与对照组有效率分别为85·7%、51·7%(P<0·05);治疗组毒副反应主要为自限性发热,12h^24h后自行恢复正常。结论:rAd-p53联合化疗控制恶性体腔积液疗效好、安全。OBJECTIVE： To evaluate the clinical efficiency of chemotherapy in the treatment of malignant body cavity effusion were randomly divided into 2 groups, The treatment group were recombinant adenovirus p53 injection （rAd- p53） combining METHODS： 50 cases with malignant body cavity effusion given intracavitary administration of rAd-p53 1 × 10^12VP after puncture drainage, 48h later which were given intracavitary administration of 60mg/ m^2 cisplatin once a week for 3-4 weeks, The control group was given the same intracavitary therapy as the treatment group but without tad - p53 therapy, RESULTS： The total effective rates of the treatment group and the control group were 85, 7% and 51, 7% （P〈 0, 05）, respectively, The toxic reaction was chiefly manifested as self- limited fever and which disappeared automatically in 12-24h, CONCLUSION： It is safe and effective to use rAd- p53 in the treatment of malignant body cavity effusion,

关 键 词：重组人P53腺病毒注射液 恶性体腔积液 基因治疗 化疗 

分 类 号：R979.1[医药卫生—药品]